Advaxis (ADXS) : Nexthera Capital Lp scooped up 44,736 additional shares in Advaxis during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 100,000 shares of Advaxis which is valued at $1,418,000.Advaxis makes up approximately 1.39% of Nexthera Capital Lp’s portfolio.
Other Hedge Funds, Including , Parametric Portfolio Associates boosted its stake in ADXS in the latest quarter, The investment management firm added 38,769 additional shares and now holds a total of 62,424 shares of Advaxis which is valued at $885,172.Citadel Advisors boosted its stake in ADXS in the latest quarter, The investment management firm added 9,714 additional shares and now holds a total of 86,115 shares of Advaxis which is valued at $1,221,111. Koshinski Asset Management sold out all of its stake in ADXS during the most recent quarter. The investment firm sold 13,822 shares of ADXS which is valued $195,996.Teacher Retirement System Of Texas boosted its stake in ADXS in the latest quarter, The investment management firm added 565 additional shares and now holds a total of 4,654 shares of Advaxis which is valued at $70,508.
Advaxis opened for trading at $11.53 and hit $11.826 on the upside on Thursday, eventually ending the session at $11.78, with a gain of 2.17% or 0.25 points. The heightened volatility saw the trading volume jump to 5,37,516 shares. Company has a market cap of $405 M.
Many Wall Street Analysts have commented on Advaxis. Company shares were Reiterated by Barclays on Aug 3, 2016 to “Overweight”, Firm has raised the Price Target to $ 20 from a previous price target of $15 .
Advaxis Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy axalimogene filolisbac (ADXS-HPV) targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer Phase I/II in head and neck cancer and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.